BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gallagher C, Nyfort-Hansen K, Rowett D, Wong CX, Middeldorp ME, Mahajan R, Lau DH, Sanders P, Hendriks JM. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart 2020;7:e001257. [PMID: 32509316 DOI: 10.1136/openhrt-2020-001257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Martínez-Montesinos L, Rivera-Caravaca JM, Agewall S, Soler E, Lip GYH, Marín F, Roldán V. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity? Biomed Pharmacother 2023;158:114064. [PMID: 36495662 DOI: 10.1016/j.biopha.2022.114064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bamgbade BA, McManus DD, Briesacher BA, Lessard D, Mehawej J, Gurwitz JH, Tisminetzky M, Mujumdar S, Wang W, Malihot T, Abu HO, Waring M, Sogade F, Madden J, Pierre-Louis IC, Helm R, Goldberg R, Kramer AF, Saczynski JS. Medication cost-reducing behaviors in older adults with atrial fibrillation: The SAGE-AF study. J Am Pharm Assoc (2003) 2023;63:125-34. [PMID: 36171156 DOI: 10.1016/j.japh.2022.08.030] [Reference Citation Analysis]
3 Caturano A, Spiezia S, Brunelli V, Galiero R, Sasso FC. Polypharmacy and Major Adverse Events in Atrial Fibrillation. J Cardiovasc Pharmacol 2022;80:781-2. [PMID: 36027584 DOI: 10.1097/FJC.0000000000001363] [Reference Citation Analysis]
4 Tsagkaris C, Papazoglou AS, Kartas A, Samaras A, Moysidis DV, Vouloagkas I, Baroutidou A, Bekiaridou A, Patsiou V, Chatzisolomou A, Panteris E, Karagiannidis E, Karvounis H, Tzikas A, Giannakoulas G. Polypharmacy and Major Adverse Events in Atrial Fibrillation. J Cardiovasc Pharmacol 2022;80:826-31. [PMID: 35921643 DOI: 10.1097/FJC.0000000000001339] [Reference Citation Analysis]
5 Gebremichael LG, Beleigoli A, Champion S, Nesbitt K, Bulto LN, Pinero de Plaza MA, Pearson V, Noonan S, Hendriks JM, Hines S, Clark RA. Effectiveness of cardiac rehabilitation programs in improving medication adherence in patients with cardiovascular disease: a systematic review protocol. JBI Evid Synth 2022;20:2986-94. [PMID: 36081378 DOI: 10.11124/JBIES-21-00457] [Reference Citation Analysis]
6 Cho HJ, Chae J, Yoon S, Kim D. Factors related to polypharmacy and hyper‐polypharmacy for the elderly: A nationwide cohort study using National Health Insurance data in South Korea. Clinical Translational Sci 2022. [DOI: 10.1111/cts.13438] [Reference Citation Analysis]
7 Romiti GF, Proietti M, Vitolo M, Bonini N, Fawzy AM, Ding WY, Fauchier L, Marin F, Nabauer M, Dan GA, Potpara TS, Boriani G, Lip GYH; ESC-EHRA EORP-AF General Long-Term Registry Investigators. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med 2022;20:326. [PMID: 36056426 DOI: 10.1186/s12916-022-02526-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zuo C, Li X, Fan L, Li J, Tian D, Chen C, Li X, Lv Q. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. J Clin Pharm Ther 2022. [PMID: 35649528 DOI: 10.1111/jcpt.13699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alfaraidhy MA, Regan C, Forman DE. Cardiac rehabilitation for older adults: current evidence and future potential. Expert Rev Cardiovasc Ther 2022. [PMID: 35098848 DOI: 10.1080/14779072.2022.2035722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang J, Yang Y, Zhu J, Zhang H, Shao X. Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes. Front Cardiovasc Med 2022;9:806234. [DOI: 10.3389/fcvm.2022.806234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Heijman J, Dobrev D. Arrhythmias. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00082-7] [Reference Citation Analysis]
12 de Terwangne C, Sorgente A, Macovei S, Preumont T, Chierchia G, de Asmundis C, de Meester A, Hanotier P. Association between atrial fibrillation, frailty, and geriatric syndromes in the late elderly in a south Belgian outpatient and inpatient setting. American Heart Journal Plus: Cardiology Research and Practice 2022;13:100106. [DOI: 10.1016/j.ahjo.2022.100106] [Reference Citation Analysis]
13 Pinho AC, Burgeiro A, Pereira MJ, Carvalho E. Drug-induced metabolic alterations in adipose tissue - with an emphasis in epicardial adipose tissue. An Acad Bras Ciênc 2022;94:e20201819. [DOI: 10.1590/0001-3765202220201819] [Reference Citation Analysis]
14 Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, Nakamura K, Onodera O, Narita I. Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study. J Bone Miner Metab 2021. [PMID: 34729651 DOI: 10.1007/s00774-021-01272-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Laliberté F, Ashton V, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Berger JS. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. J Comp Eff Res 2021. [PMID: 34378989 DOI: 10.2217/cer-2021-0150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Fujisawa T, Arita T, Suzuki S, Yagi N, Otsuka T, Kishi M, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Matsuhama M, Iida M, Yajima J, Yamashita T. Relationship between number of medications and incidence of falls or bone fracture in elderly patients with non-valvular atrial fibrillation: Shinken database analysis. Geriatr Gerontol Int 2021;21:802-9. [PMID: 34268840 DOI: 10.1111/ggi.14242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shakhmatova OO, Panchenko EP, Balakhonova TV, Makeev MI, Mironov VM, Blankova ZN, Butorova EA. Cardiomyopathy and multiple arterial thrombosis in a patient with severe tachyform atrial fibrillation after COVID-19. Aterotromboz 2021. [DOI: 10.21518/2307-1109-2021-11-1-6-24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med 2021;12:443-52. [PMID: 33694123 DOI: 10.1007/s41999-021-00479-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
19 Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol 2021;18:276-90. [PMID: 33110242 DOI: 10.1038/s41569-020-00459-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
20 Iturbe-Hernandez T, García de Guadiana Romualdo L, Gil Ortega I, Martínez Francés A, Meca Birlanga O, Cerezo-Manchado JJ. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol. Drugs Context 2020;9:2020-8-3. [PMID: 33014097 DOI: 10.7573/dic.2020-8-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
21 Hendriks J, Gallagher C, Nyfort-Hansen K, Lau D, Sanders P. Adherence to anticoagulation therapy in patients with atrial fibrillation: is a tailored team-based approach warranted? Heart 2020;106:1710-1. [PMID: 32769170 DOI: 10.1136/heartjnl-2020-317478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]